Free Trial
NASDAQ:ASRT

Assertio Q1 2025 Earnings Report

Assertio logo
$0.62 +0.01 (+1.16%)
Closing price 05/7/2025 04:00 PM Eastern
Extended Trading
$0.61 -0.01 (-0.83%)
As of 05/7/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Assertio EPS Results

Actual EPS
N/A
Consensus EPS
-$0.03
Beat/Miss
N/A
One Year Ago EPS
N/A

Assertio Revenue Results

Actual Revenue
N/A
Expected Revenue
$27.52 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Assertio Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Monday, May 12, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Assertio Earnings Headlines

Assertio (ASRT) Projected to Post Earnings on Monday
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Assertio price target lowered to $1.75 from $2.15 at Alliance Global
See More Assertio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Assertio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Assertio and other key companies, straight to your email.

About Assertio

Assertio (NASDAQ:ASRT), a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

View Assertio Profile

More Earnings Resources from MarketBeat